These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32790160)

  • 21. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
    Meng A; Humeniuk R; Jürgensmeier JM; Hsueh CH; Matzkies F; Grant E; Truong H; Billin AN; Yu H; Feng J; Kwan E; Tarnowski T; Nelson CH
    Clin Pharmacol Ther; 2022 Feb; 111(2):416-424. PubMed ID: 34623640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
    Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Gua C; Liu Y; Liu Y; Lulla M; Marcotte D; Marx I; McDowell B; Mertsching E; Negrou E; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M
    Bioorg Med Chem; 2021 Aug; 44():116275. PubMed ID: 34314938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
    Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
    Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
    Zhao G; Liu A; Zhang Y; Zuo ZQ; Cao ZT; Zhang HB; Xu CF; Wang J
    Biomater Sci; 2019 Nov; 7(11):4698-4707. PubMed ID: 31495833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
    Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
    Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
    Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.
    Fang X; Liu C; Zhang K; Yang W; Wu Z; Shen S; Ma Y; Lu X; Chen Y; Lu T; Hu Q; Jiang Y
    Eur J Med Chem; 2023 Jan; 246():114940. PubMed ID: 36462441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
    J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
    J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.